Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
May 02 2024 - 8:00AM
Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of
AI and RNA editing to revolutionize genomic medicine, is pleased to
announce the appointment of Matt Valentino as Chief People Officer.
Before joining ShapeTX, Matt was at the helm of diverse People
teams for notable biotech and technology companies including Calico
Labs, Genentech, Pandora, Validant, and DoorDash.
“Matt brings extensive experience in leading teams at scientific
R&D companies focused on drug development, manufacturing,
robotics, and AI/ML applications. As an early team member at Calico
Labs, he played a crucial role in scaling the company from 70 to
over 300 employees, including the expansion of their Drug
Discovery, Computational and Clinical Development teams. While at
DoorDash, Matt facilitated growth from 2,000 to over 17,000 global
employees. His expertise will be instrumental in guiding ShapeTX
through its next growth phase as we continue to innovate at the
intersection of technology and biotechnology," said Francois
Vigneault, Ph.D., Co-Founder and CEO of ShapeTX. "We are confident
in Matt's leadership and excited about the future developments he
will drive at ShapeTX." Matt added, "I’m thrilled to join the
talented team at ShapeTX, and I am eager to advance our mission of
repairing genetic causes of disease with programmable RNA
medicines."
About ShapeTXShape Therapeutics operates at the
convergence of AI and RNA editing to revolutionize genomic
medicine. Our proprietary RNA editing technology, RNAfix®,
represents a significant leap forward over CRISPR-based tools,
achieving 95% editing efficiency in vivo, and a path to one-time
curative treatments for thousands of diseases. With over 90 million
laboratory-validated guide RNA data points and 12 billion
NHP-derived AAVs, ShapeTX is building the largest RNA foundation
model in the industry. Having secured strategic collaborations
worth over $4 billion with industry-leading pharmaceutical firms,
ShapeTX is poised for substantial growth and to cement our position
as a leader in AI for genomic medicine. You can find us
at ShapeTX.com and on LinkedIn and X.
Contact:Gary Fortin, PhDgary@shapetx.com